Plasma exchange study for anti-MDA5 antibody positive interstitial pneumonia
Phase 3
Recruiting
- Conditions
- Interstitial lung disease with anti-MDA5 antibodyInterstitial lung disease
- Registration Number
- JPRN-jRCTs032180260
- Lead Sponsor
- Tamura Naoto
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
1.Age=>20 years old
2.Patients diagnosed as new onset or relapse of anti-MDA5 antibody positive interstitial lung disease
3.Treatment resistance to standard therapy
4.Written informed consent
Exclusion Criteria
1. Unable to provide informed consent
2. Patients with poor control complications
3. Weighing less than 40 kg
4. Pregnant or lactating women, having pregnancy plan within 52 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1 year survival rate
- Secondary Outcome Measures
Name Time Method medicine dose, adverse reaction ratio, blood/ urinalysis data, chest image